Federal contract award
75N95023F00003
MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N95022D00021 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $10.6M |
| Current contract value | $10.6M |
| Potential contract value / ceiling | $12.6M |
| Start date | Sep 30, 2023 |
| Current end date | Sep 29, 2030 |
| Potential end date | Sep 29, 2030 |
| Latest award activity | Jun 1, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 1, 2026 | P00006 | $1.3M | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
| Aug 29, 2025 | P00005 | $94.1K | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
| Mar 27, 2025 | P00004 | $2.6M | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
| Nov 27, 2024 | P00003 | $3.9M | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
| Nov 26, 2024 | P00002 | $490.7K | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
| Aug 15, 2024 | P00001 | $131.7K | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
| Sep 28, 2023 | 0 | $2.1M | MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES IN NORMAL RATS AND NORMAL NHPS |
Estimated positioning window
Sep 29, 2029 – Mar 29, 2030
55/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 55/100. Available recorded signals: 50 points.
- Contract end 2030-09-29 (1428 days from calculation)
- +5 points
- 12 historical awards in this buyer and category group
- +15 points
- 7 recorded award transactions
- +10 points
- Latest award action: 2026-06-01
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.